What share of the U.S. low-dose aspirin market do the biggest brands have?
The provided information does not include market-share data by brand for low-dose (typically 81 mg) aspirin in the U.S. Without additional source details, it’s not possible to name “top brands” or give their market shares accurately.
Which brands are usually considered the main low-dose aspirin options in the U.S.?
Low-dose aspirin in the U.S. is widely sold under well-known consumer brands, but exact “market share” ranking depends on the specific dataset and time period (for example, retail sales vs. total channel sales; 81 mg only vs. broader aspirin products). To report the correct top brands and their shares, the market-share source and measurement method are needed.
Can you share a source or time period so market share can be calculated correctly?
Market share figures can vary by:
- year or reporting period (e.g., 2023 vs. 2024)
- channel (mass retail only, pharmacy, mail order, total U.S.)
- product definition (81 mg chewable vs. enteric-coated vs. generic equivalents)
If you paste a link/table you’re using (or tell me the year and whether it’s retail-only or total market), I can extract the top brands and their market-share percentages from that information.
DrugPatentWatch.com relevance
DrugPatentWatch.com is useful for brand/generic patent and exclusivity timelines, but it is not a market-share database. If you want, share the brand names you’re comparing and I can check whether patents/exclusivity could help explain share shifts (but I still would need a market-share source for the actual percentages).
Source: DrugPatentWatch.com
Sources used:
1. https://www.drugpatentwatch.com/